Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 543

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 543
---
 equivalents, may be insufficient to enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. If these sources are insufficient to satisfy our liquidity requirements, we may seek to raise additional funds through equity offerings, debt financings, collaborations, government contracts or other strategic transactions. 338

Cash Flows The following table summarizes our cash flows for each of the periods presented (in thousands):

| Net cash and cash equivalents (used for) provided by: |     | Three Months    
 Ended March 31, 
 2025            |      |   |     | 2024 |        |   |
|:------------------------------------------------------|:----|:----------------|-----:|:--|:----|:-----|-------:|:--|
| Operating activities                                  |     | $               | (399 | ) |     | $    | (2,159 | ) |
| Financing activities                                  |     |                 |  394 |   |     |      |  2,164 |   |
| Net change in cash and cash equivalents               |     | $               |   (5 | ) |     | $    |      5 |   |

|                                                       |     | Year Ended   
 December 31, |   2024 |   |     |   |   2023 |   |
|:------------------------------------------------------|:----|:-------------|-------:|:--|:----|:--|-------:|:--|
| Net cash and cash equivalents (used for) provided by: |     |              |        |   |     |   |        |   |
| Operating activities                                  |     | $            | (4,891 | ) |     | $ | (1,677 | ) |
| Financing activities                                  |     |              |  4,891 |   |     |   |  1,661 |   |
| Net change in cash and cash equivalents               |     | $            |      — |   |     | $ |    (16 | ) |

Cash Flows from Operating Activities For the three months ended March 31, 2025, net cash used for operating activities was approximately $0.4 million, attributable to our net loss of $0.7 million, partially offset by stock-based compensation of $0.1 million and changes in operating assets and liabilities that provided $0.2 million of cash. For the three months ended March 31, 2024, net cash used for operating